Genmab A/S (OTCMKTS:GNMSF) Sees Significant Decline in Short Interest

Genmab A/S (OTCMKTS:GNMSF) saw a significant drop in short interest during the month of December. As of December 15th, there was short interest totaling 72,780 shares, a drop of 21.7% from the November 30th total of 92,975 shares. Based on an average daily trading volume, of 5,512 shares, the days-to-cover ratio is presently 13.2 days. Approximately 0.1% of the company’s stock are short sold. Approximately 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 5,512 shares, the days-to-cover ratio is presently 13.2 days.

Genmab A/S Price Performance

GNMSF opened at $333.25 on Tuesday. The company has a market cap of $22.02 billion, a P/E ratio of 14.21 and a beta of 0.88. The firm’s 50-day moving average price is $308.11 and its 200-day moving average price is $270.48. Genmab A/S has a 52-week low of $170.00 and a 52-week high of $336.45.

Genmab A/S (OTCMKTS:GNMSF) last released its earnings results on Thursday, November 6th. The company reported $6.46 earnings per share for the quarter, topping the consensus estimate of $4.86 by $1.60. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%.

About Genmab A/S

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.